Compare Google Inc (GOOG) vs 10X Genomics Inc (TXG) Price & Performance

Alphabet (GOOG) trades at $355.84, up 0.67% on the day, with a bullish technical signal from moving averages and strong quarterly earnings beats. The company reported robust revenue growth to $402.84 billion in 2025, with net income surging to $132.17 billion, and announced a new AI leadership structure to accelerate Gemini development amid rising user adoption.

Outlook remains positive with an 86.84% analyst buy rating and a $431.67 consensus price target, though risks include high capital expenditure for AI infrastructure and regulatory scrutiny. The stock offers growth potential from AI monetization but faces volatility from tech sector pressures and antitrust investigations.

TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.

Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.